Company Profile
Vir Biotechnology Stock Price, News & Catalysts
- Ticker:
- VIR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
9.91 USD (+1.33%)
Close
Last updated: August 24, 2026
1.47B USD
Market cap
Why the stock is moving
As of Aug 24, 2026, VIR closed up 1.33% at $9.91. No new same-company headline was identified in the current news window.
Company overview
Business overview
Vir Biotechnology is an immunology and infectious-disease company built around antibody science and platform partnerships.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Vir sits in specialty biotechnology.
Business Model Characteristics
Its model depends on clinical development, collaboration revenue, and finding durable programs beyond the pandemic era.
Position Within the Biotechnology Landscape
Vir remains a platform-heavy biotech name, but investors need the pipeline to deliver clear differentiation to keep the story moving.
Future catalysts
- Vir Biotechnology's catalysts are tobevibart plus elebsiran in hepatitis D, along with the rest of the hepatitis B franchise. The stock will care about whether the antiviral platform can keep finding a clear regulatory and commercial path.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Vir Biotechnology (VIR)?
Vir Biotechnology (VIR) most recently closed at 9.91 USD, a +1.33% move versus the previous session.
What is the market cap of Vir Biotechnology (VIR)?
Vir Biotechnology currently has a market capitalization of 1.47B USD on BioPharmSignal.
What does Vir Biotechnology do?
Vir Biotechnology is an immunology and infectious-disease company built around antibody science and platform partnerships.
On which exchange is VIR stock listed?
Vir Biotechnology (VIR) is associated with NASDAQ, United States, Biopharma.
What is Biotechnology?
Vir Biotechnology's catalysts are tobevibart plus elebsiran in hepatitis D, along with the rest of the hepatitis B franchise.
Which conditions is Vir Biotechnology targeting with Biotechnology?
Vir Biotechnology is associated with immunology based on its company overview and current catalyst commentary.
How does Vir Biotechnology describe recent progress with Biotechnology?
Vir Biotechnology's catalysts are tobevibart plus elebsiran in hepatitis D, along with the rest of the hepatitis B franchise.
What future catalysts are investors watching for Vir Biotechnology?
Vir Biotechnology's catalysts are tobevibart plus elebsiran in hepatitis D, along with the rest of the hepatitis B franchise. The stock will care about whether the antiviral platform can keep finding a clear regulatory and commercial path.